

References

1. Hanahan, D. and R.A. Weinberg, *The hallmarks of cancer*. Cell, 2000. **100**(1): p. 57-70.
2. Sariego, J., *Breast cancer in the young patient*. Am Surg, 2010. **76**(12): p. 1397-400.
3. Reeder, J.G. and V.G. Vogel, *Breast cancer prevention*. Cancer Treat Res, 2008. **141**: p. 149-64.
4. Collaborative Group on Hormonal Factors in Breast, C., *Breast cancer and breastfeeding: collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50302 women with breast cancer and 96973 women without the disease*. Lancet, 2002. **360**(9328): p. 187-95.
5. Yager, J.D. and N.E. Davidson, *Estrogen carcinogenesis in breast cancer*. N Engl J Med, 2006. **354**(3): p. 270-82.
6. Blackburn, G.L. and K.A. Wang, *Dietary fat reduction and breast cancer outcome: results from the Women's Intervention Nutrition Study (WINS)*. Am J Clin Nutr, 2007. **86**(3): p. s878-81.
7. Boffetta, P., et al., *The burden of cancer attributable to alcohol drinking*. Int J Cancer, 2006. **119**(4): p. 884-7.
8. Johnson, K.C., et al., *Active smoking and secondhand smoke increase breast cancer risk: the report of the Canadian Expert Panel on Tobacco Smoke and Breast Cancer Risk (2009)*. Tob Control, 2011. **20**(1): p. e2.
9. Lee, I.M., et al., *Effect of physical inactivity on major non-communicable diseases worldwide: an analysis of burden of disease and life expectancy*. Lancet, 2012. **380**(9838): p. 219-29.
10. Hendrick, R.E., *Radiation doses and cancer risks from breast imaging studies*. Radiology, 2010. **257**(1): p. 246-53.

11. Brody, J.G., et al., *Environmental pollutants, diet, physical activity, body size, and breast cancer: where do we stand in research to identify opportunities for prevention?* Cancer, 2007. **109**(12 Suppl): p. 2627-34.
12. Ferro, R., *Pesticides and Breast Cancer*. Advances in Breast Cancer Research, 2012. **01**(03): p. 30-35.
13. Dunning, A.M., et al., *A systematic review of genetic polymorphisms and breast cancer risk*. Cancer Epidemiol Biomarkers Prev, 1999. **8**(10): p. 843-54.
14. Rahman, N. and M.R. Stratton, *The genetics of breast cancer susceptibility*. Annu Rev Genet, 1998. **32**: p. 95-121.
15. Gabriel, A. and A. Ashworth, *The breast cancer susceptibility genes BRCA1 and BRCA2*, in *Targets for cancer therapy. Transcription factors and other nuclear proteins*, L. Thangue and L.R. Bandra, Editors. 2002, Humana Press Inc.: NJ.
16. Saslow, D., et al., *Clinical breast examination: practical recommendations for optimizing performance and reporting*. CA Cancer J Clin, 2004. **54**(6): p. 327-44.
17. Merck Manual, P.E., Ch. 253, Breast Cancer.
18. Yu, Y.H., C. Liang, and X.Z. Yuan, *Diagnostic value of vacuum-assisted breast biopsy for breast carcinoma: a meta-analysis and systematic review*. Breast Cancer Res Treat, 2010. **120**(2): p. 469-79.
19. Feuer, E.J., et al., *The lifetime risk of developing breast cancer*. J Natl Cancer Inst, 1993. **85**(11): p. 892-7.
20. Sotiriou, C. and L. Pusztai, *Gene-expression signatures in breast cancer*. N Engl J Med, 2009. **360**(8): p. 790-800.
21. Romond, E.H., et al., *Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer*. N Engl J Med, 2005. **353**(16): p. 1673-84.
22. Peppercorn, J., *Breast cancer in women under 40*. Oncology (Williston Park), 2009. **23**(6): p. 465-74.

23. Eliassen, A.H., et al., *Physical activity and risk of breast cancer among postmenopausal women*. Arch Intern Med, 2010. **170**(19): p. 1758-64.
24. Zheng, J.S., et al., *Intake of fish and marine n-3 polyunsaturated fatty acids and risk of breast cancer: meta-analysis of data from 21 independent prospective cohort studies*. BMJ, 2013. **346**: p. f3706.
25. Hartmann, L.C., et al., *Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer*. N Engl J Med, 1999. **340**(2): p. 77-84.
26. Nelson, H.D., et al., *Use of medications to reduce risk for primary breast cancer: a systematic review for the U.S. Preventive Services Task Force*. Ann Intern Med, 2013. **158**(8): p. 604-14.
27. Saini, K.S., et al., *Role of the multidisciplinary team in breast cancer management: results from a large international survey involving 39 countries*. Ann Oncol, 2012. **23**(4): p. 853-9.
28. Dowsett, M. and P.E. Lonning, *Anastrozole--a new generation in aromatase inhibition: clinical pharmacology*. Oncology, 1997. **54 Suppl 2**: p. 11-4.
29. Sotiriou, C. and L. Pusztai, *Gene-Expression Signatures in Breast Cancer*. New England Journal of Medicine, 2009. **360**(8): p. 790-800.
30. Romond, E.H., et al., *Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer*. New England Journal of Medicine, 2005. **353**(16): p. 1673-1684.
31. Belletti, B., et al., *Targeted intraoperative radiotherapy impairs the stimulation of breast cancer cell proliferation and invasion caused by surgical wounding*. Clin Cancer Res, 2008. **14**(5): p. 1325-32.
32. Neve, R.M., et al., *A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes*. Cancer Cell, 2006. **10**(6): p. 515-27.

33. Lasfargues, E.Y. and L. Ozzello, *Cultivation of human breast carcinomas*. J Natl Cancer Inst, 1958. **21**(6): p. 1131-47.
34. Lasfargues, E.Y., W.G. Coutinho, and E.S. Redfield, *Isolation of two human tumor epithelial cell lines from solid breast carcinomas*. J Natl Cancer Inst, 1978. **61**(4): p. 967-78.
35. Borrás, M., et al., *Estrogen receptor-negative/progesterone receptor-positive Evsa-T mammary tumor cells: a model for assessing the biological property of this peculiar phenotype of breast cancers*. Cancer Lett, 1997. **120**(1): p. 23-30.
36. Hackett, A.J., et al., *Two syngeneic cell lines from human breast tissue: the aneuploid mammary epithelial (Hs578T) and the diploid myoepithelial (Hs578Bst) cell lines*. J Natl Cancer Inst, 1977. **58**(6): p. 1795-806.
37. Soule, H.D., et al., *A human cell line from a pleural effusion derived from a breast carcinoma*. J Natl Cancer Inst, 1973. **51**(5): p. 1409-16.
38. Cailleau, R., et al., *Breast tumor cell lines from pleural effusions*. J Natl Cancer Inst, 1974. **53**(3): p. 661-74.
39. Engel, L.W. and N.A. Young, *Human breast carcinoma cells in continuous culture: a review*. Cancer Res, 1978. **38**(11 Pt 2): p. 4327-39.
40. Keydar, I., et al., *Establishment and characterization of a cell line of human breast carcinoma origin*. Eur J Cancer, 1979. **15**(5): p. 659-70.
41. Levenson, A.S. and V.C. Jordan, *MCF-7: the first hormone-responsive breast cancer cell line*. Cancer Res, 1997. **57**(15): p. 3071-8.
42. Lacroix, M. and G. Leclercq, *Relevance of breast cancer cell lines as models for breast tumours: an update*. Breast Cancer Res Treat, 2004. **83**(3): p. 249-89.
43. Ross, D.T. and C.M. Perou, *A comparison of gene expression signatures from breast tumors and breast tissue derived cell lines*. Dis Markers, 2001. **17**(2): p. 99-109.

44. Charafe-Jauffret, E., et al., *Gene expression profiling of breast cell lines identifies potential new basal markers*. *Oncogene*, 2006. **25**(15): p. 2273-84.
45. Lacroix, M., R.A. Toillon, and G. Leclercq, *p53 and breast cancer, an update*. *Endocr Relat Cancer*, 2006. **13**(2): p. 293-325.
46. Collins, L.G., et al., *Lung cancer: diagnosis and management*. *Am Fam Physician*, 2007. **75**(1): p. 56-63.
47. Leora Horn, William Pao, and D.H. Johnson, *Neoplasms of the Lung*, in *Harrison's Principles of Internal Medicine*. 2012, McGraw-Hill: Singapore.
48. Ferlay, J., et al., *Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008*. *Int J Cancer*, 2010. **127**(12): p. 2893-917.
49. Coglianò, V.J., et al., *Preventable exposures associated with human cancers*. *J Natl Cancer Inst*, 2011. **103**(24): p. 1827-39.
50. Fong, K.M., et al., *Lung cancer. 9: Molecular biology of lung cancer: clinical implications*. *Thorax*, 2003. **58**(10): p. 892-900.
51. Salgia, R. and A.T. Skarin, *Molecular abnormalities in lung cancer*. *J Clin Oncol*, 1998. **16**(3): p. 1207-17.
52. Herbst, R.S., J.V. Heymach, and S.M. Lippman, *Lung cancer*. *N Engl J Med*, 2008. **359**(13): p. 1367-80.
53. Rosti, G., et al., *Small cell lung cancer*. *Ann Oncol*, 2006. **17 Suppl 2**: p. ii5-10.
54. Rami-Porta, R., J.J. Crowley, and P. Goldstraw, *The revised TNM staging system for lung cancer*. *Ann Thorac Cardiovasc Surg*, 2009. **15**(1): p. 4-9.
55. Boiselle, P.M., *Computed tomography screening for lung cancer*. *JAMA*, 2013. **309**(11): p. 1163-70.
56. Bach, P.B., et al., *Benefits and harms of CT screening for lung cancer: a systematic review*. *JAMA*, 2012. **307**(22): p. 2418-29.

57. McNabola, A. and L.W. Gill, *The control of environmental tobacco smoke: a policy review*. Int J Environ Res Public Health, 2009. **6**(2): p. 741-58.
58. Dimitropoulos, C., et al., *Prophylactic cranial irradiation in non-small cell lung cancer patients: who might be the candidates?* Cancer Manag Res, 2011. **3**: p. 287-94.
59. Giard, D.J., et al., *In vitro cultivation of human tumors: establishment of cell lines derived from a series of solid tumors*. J Natl Cancer Inst, 1973. **51**(5): p. 1417-23.
60. Couse, J.F. and K.S. Korach, *Estrogen receptor null mice: what have we learned and where will they lead us?* Endocr Rev, 1999. **20**(3): p. 358-417.
61. Förster, C., et al., *Involvement of estrogen receptor β in terminal differentiation of mammary gland epithelium*. Proceedings of the National Academy of Sciences, 2002. **99**(24): p. 15578-15583.
62. Weihua, Z., et al., *A role for estrogen receptor beta in the regulation of growth of the ventral prostate*. Proc Natl Acad Sci U S A, 2001. **98**(11): p. 6330-5.
63. Wang, L., et al., *Morphological abnormalities in the brains of estrogen receptor beta knockout mice*. Proc Natl Acad Sci U S A, 2001. **98**(5): p. 2792-6.
64. Morani, A., et al., *Lung dysfunction causes systemic hypoxia in estrogen receptor beta knockout (ERbeta^{-/-}) mice*. Proc Natl Acad Sci U S A, 2006. **103**(18): p. 7165-9.
65. Heldring, N., et al., *Estrogen receptors: how do they signal and what are their targets*. Physiol Rev, 2007. **87**(3): p. 905-31.
66. Ponglikitmongkol, M., S. Green, and P. Chambon, *Genomic organization of the human oestrogen receptor gene*. EMBO J, 1988. **7**(11): p. 3385-8.
67. Enmark, E., et al., *Human estrogen receptor beta-gene structure, chromosomal localization, and expression pattern*. J Clin Endocrinol Metab, 1997. **82**(12): p. 4258-65.

68. Ogawa, S., et al., *The complete primary structure of human estrogen receptor beta (hER beta) and its heterodimerization with ER alpha in vivo and in vitro*. *Biochem Biophys Res Commun*, 1998. **243**(1): p. 122-6.
69. Tora, L., et al., *The human estrogen receptor has two independent nonacidic transcriptional activation functions*. *Cell*, 1989. **59**(3): p. 477-487.
70. Adler, S., et al., *Steroid receptor-mediated inhibition of rat prolactin gene expression does not require the receptor DNA-binding domain*. *Cell*, 1988. **52**(5): p. 685-95.
71. Oosterkamp HM and Bernards R, *Androgen receptors and estrogen receptors*, in *Targets of cancer chemotherapy: Transcription factors and other nuclear proteins*, N.B. La Thangue and L.R. Bandara, Editors. 2004, Human Press: Totowa, NJ. p. 315-331.
72. Mueller, S.O. and K.S. Korach, *Estrogen receptors and endocrine diseases: lessons from estrogen receptor knockout mice*. *Curr Opin Pharmacol*, 2001. **1**(6): p. 613-9.
73. Osborne, C.K., *Tamoxifen in the treatment of breast cancer*. *N Engl J Med*, 1998. **339**(22): p. 1609-18.
74. Lindberg, K., et al., *Expression of estrogen receptor beta increases integrin alpha1 and integrin beta1 levels and enhances adhesion of breast cancer cells*. *J Cell Physiol*, 2010. **222**(1): p. 156-67.
75. Klinge, C.M., *Estrogen receptor interaction with estrogen response elements*. *Nucleic Acids Research*, 2001. **29**(14): p. 2905-2919.
76. Kushner, P.J., et al., *Estrogen receptor pathways to AP-1*. *J Steroid Biochem Mol Biol*, 2000. **74**(5): p. 311-7.
77. Saville, B., et al., *Ligand-, cell-, and estrogen receptor subtype (alpha/beta)-dependent activation at GC-rich (Sp1) promoter elements*. *J Biol Chem*, 2000. **275**(8): p. 5379-87.

78. Webb, P., et al., *The estrogen receptor enhances AP-1 activity by two distinct mechanisms with different requirements for receptor transactivation functions*. Mol Endocrinol, 1999. **13**(10): p. 1672-85.
79. Umayahara, Y., et al., *Estrogen regulation of the insulin-like growth factor I gene transcription involves an AP-1 enhancer*. J Biol Chem, 1994. **269**(23): p. 16433-42.
80. Schmitt, M., et al., *Positive and negative effects of nuclear receptors on transcription activation by AP-1 of the human choline acetyltransferase proximal promoter*. J Neurosci Res, 1995. **40**(2): p. 152-64.
81. Shen, Q., et al., *The AP-1 transcription factor regulates breast cancer cell growth via cyclins and E2F factors*. Oncogene, 2008. **27**(3): p. 366-77.
82. Angel, P., et al., *12-O-tetradecanoyl-phorbol-13-acetate induction of the human collagenase gene is mediated by an inducible enhancer element located in the 5'-flanking region*. Mol Cell Biol, 1987. **7**(6): p. 2256-66.
83. Bohmann, D., et al., *Human proto-oncogene c-jun encodes a DNA binding protein with structural and functional properties of transcription factor AP-1*. Science, 1987. **238**(4832): p. 1386-92.
84. Xia, Y., et al., *c-Jun downregulation by HDAC3-dependent transcriptional repression promotes osmotic stress-induced cell apoptosis*. Mol Cell, 2007. **25**(2): p. 219-32.
85. Hess, J., P. Angel, and M. Schorpp-Kistner, *AP-1 subunits: quarrel and harmony among siblings*. J Cell Sci, 2004. **117**(Pt 25): p. 5965-73.
86. Carlone, D.L. and J.S. Richards, *Functional interactions, phosphorylation, and levels of 3',5'-cyclic adenosine monophosphate-regulatory element binding protein and steroidogenic factor-1 mediate hormone-regulated and constitutive expression of aromatase in gonadal cells*. Mol Endocrinol, 1997. **11**(3): p. 292-304.

87. Chinenov, Y. and T.K. Kerppola, *Close encounters of many kinds: Fos-Jun interactions that mediate transcription regulatory specificity*. *Oncogene*, 2001. **20**(19): p. 2438-52.
88. Gruda, M.C., et al., *Regulation of Fra-1 and Fra-2 phosphorylation differs during the cell cycle of fibroblasts and phosphorylation in vitro by MAP kinase affects DNA binding activity*. *Oncogene*, 1994. **9**(9): p. 2537-47.
89. Angel, P. and M. Karin, *The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation*. *Biochim Biophys Acta*, 1991. **1072**(2-3): p. 129-57.
90. Webb, P., et al., *Tamoxifen activation of the estrogen receptor/AP-1 pathway: potential origin for the cell-specific estrogen-like effects of antiestrogens*. *Mol Endocrinol*, 1995. **9**(4): p. 443-56.
91. Paech, K., et al., *Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites*. *Science*, 1997. **277**(5331): p. 1508-10.
92. Schiff, R., et al., *Oxidative stress and AP-1 activity in tamoxifen-resistant breast tumors in vivo*. *J Natl Cancer Inst*, 2000. **92**(23): p. 1926-34.
93. Brown, P.H., et al., *Suppression of oncogene-induced transformation by a deletion mutant of c-jun*. *Oncogene*, 1993. **8**(4): p. 877-86.
94. Rapp, U.R., et al., *Transformation by Raf and other oncogenes renders cells differentially sensitive to growth inhibition by a dominant negative c-jun mutant*. *Oncogene*, 1994. **9**(12): p. 3493-8.
95. Hennigan, R.F., K.L. Hawker, and B.W. Ozanne, *Fos-transformation activates genes associated with invasion*. *Oncogene*, 1994. **9**(12): p. 3591-600.
96. Lamb, R.F., et al., *AP-1-mediated invasion requires increased expression of the hyaluronan receptor CD44*. *Mol Cell Biol*, 1997. **17**(2): p. 963-76.

97. Johnston, I.M., et al., *Regulation of a multigenic invasion programme by the transcription factor, AP-1: re-expression of a down-regulated gene, TSC-36, inhibits invasion.* *Oncogene*, 2000. **19**(47): p. 5348-58.
98. Karin, M., Z. Liu, and E. Zandi, *AP-1 function and regulation.* *Curr Opin Cell Biol*, 1997. **9**(2): p. 240-6.
99. Maki, Y., et al., *Avian sarcoma virus 17 carries the jun oncogene.* *Proc Natl Acad Sci U S A*, 1987. **84**(9): p. 2848-52.
100. Hattori, K., et al., *Structure and chromosomal localization of the functional intronless human JUN protooncogene.* *Proc Natl Acad Sci U S A*, 1988. **85**(23): p. 9148-52.
101. Landschulz, W.H., P.F. Johnson, and S.L. McKnight, *The leucine zipper: a hypothetical structure common to a new class of DNA binding proteins.* *Science*, 1988. **240**(4860): p. 1759-64.
102. Gentz, R., et al., *Parallel association of Fos and Jun leucine zippers juxtaposes DNA binding domains.* *Science*, 1989. **243**(4899): p. 1695-9.
103. Turner, R. and R. Tjian, *Leucine repeats and an adjacent DNA binding domain mediate the formation of functional cFos-cJun heterodimers.* *Science*, 1989. **243**(4899): p. 1689-94.
104. Chida, K. and P.K. Vogt, *Nuclear translocation of viral Jun but not of cellular Jun is cell cycle dependent.* *Proc Natl Acad Sci U S A*, 1992. **89**(10): p. 4290-4.
105. Treier, M., L.M. Staszewski, and D. Bohmann, *Ubiquitin-dependent c-Jun degradation in vivo is mediated by the delta domain.* *Cell*, 1994. **78**(5): p. 787-98.
106. Sabapathy, K., et al., *Distinct roles for JNK1 and JNK2 in regulating JNK activity and c-Jun-dependent cell proliferation.* *Mol Cell*, 2004. **15**(5): p. 713-25.
107. Leppa, S., et al., *Differential regulation of c-Jun by ERK and JNK during PC12 cell differentiation.* *EMBO J*, 1998. **17**(15): p. 4404-13.

108. Morton, S., et al., *A reinvestigation of the multisite phosphorylation of the transcription factor c-Jun*. EMBO J, 2003. **22**(15): p. 3876-86.
109. Boyle, W.J., et al., *Activation of protein kinase C decreases phosphorylation of c-Jun at sites that negatively regulate its DNA-binding activity*. Cell, 1991. **64**(3): p. 573-84.
110. Bannister, A.J., et al., *Stimulation of c-Jun activity by CBP: c-Jun residues Ser63/73 are required for CBP induced stimulation in vivo and CBP binding in vitro*. Oncogene, 1995. **11**(12): p. 2509-14.
111. Eriksson, M., *AP-1 transcription factor in cell differentiation and survival*, in *Molecular and Cancer Biology Research Program, Faculty of Medicine*. 2005, University of Helsinki. p. 1-68.
112. Kallunki, T., et al., *c-Jun can recruit JNK to phosphorylate dimerization partners via specific docking interactions*. Cell, 1996. **87**(5): p. 929-39.
113. Li, B., et al., *Regulation of IL-4 expression by the transcription factor JunB during T helper cell differentiation*. EMBO J, 1999. **18**(2): p. 420-432.
114. Chiu, R., P. Angel, and M. Karin, *Jun-B differs in its biological properties from, and is a negative regulator of, c-Jun*. Cell, 1989. **59**(6): p. 979-86.
115. Babu, R.L., et al., *Effect of estrogen and tamoxifen on the expression pattern of AP-1 factors in MCF-7 cells: role of c-Jun, c-Fos, and Fra-1 in cell cycle regulation*. Mol Cell Biochem, 2013. **380**(1-2): p. 143-51.
116. Bamberger, A.M., et al., *Expression pattern of the AP-1 family in breast cancer: association of fosB expression with a well-differentiated, receptor-positive tumor phenotype*. Int J Cancer, 1999. **84**(5): p. 533-8.
117. Thepot, D., et al., *Targeted disruption of the murine junD gene results in multiple defects in male reproductive function*. Development, 2000. **127**(1): p. 143-53.
118. Ricci, R., et al., *Distinct functions of junD in cardiac hypertrophy and heart failure*. Genes Dev, 2005. **19**(2): p. 208-13.

119. Hirai, S.I., et al., *Characterization of junD: a new member of the jun proto-oncogene family*. EMBO J, 1989. **8**(5): p. 1433-9.
120. Ryder, K., et al., *jun-D: a third member of the jun gene family*. Proc Natl Acad Sci U S A, 1989. **86**(5): p. 1500-3.
121. Weitzman, J.B., et al., *JunD protects cells from p53-dependent senescence and apoptosis*. Mol Cell, 2000. **6**(5): p. 1109-19.
122. Meixner, A., et al., *JunD regulates lymphocyte proliferation and T helper cell cytokine expression*. EMBO J, 2004. **23**(6): p. 1325-35.
123. Pfarr, C.M., et al., *Mouse JunD negatively regulates fibroblast growth and antagonizes transformation by ras*. Cell, 1994. **76**(4): p. 747-60.
124. Sharma, S.C. and J.S. Richards, *Regulation of AP1 (Jun/Fos) factor expression and activation in ovarian granulosa cells. Relation of JunD and Fra2 to terminal differentiation*. J Biol Chem, 2000. **275**(43): p. 33718-28.
125. Gallo, A., et al., *Menin uncouples Elk-1, JunD and c-Jun phosphorylation from MAP kinase activation*. Oncogene, 2002. **21**(42): p. 6434-45.
126. Naito, J., et al., *Menin suppresses osteoblast differentiation by antagonizing the AP-1 factor, JunD*. J Biol Chem, 2005. **280**(6): p. 4785-91.
127. Curran, T., et al., *FBJ murine osteosarcoma virus: identification and molecular cloning of biologically active proviral DNA*. J Virol, 1982. **44**(2): p. 674-82.
128. Rauscher, F.J., 3rd, et al., *Common DNA binding site for Fos protein complexes and transcription factor AP-1*. Cell, 1988. **52**(3): p. 471-80.
129. Greenberg, M.E. and E.B. Ziff, *Stimulation of 3T3 cells induces transcription of the c-fos proto-oncogene*. Nature, 1984. **311**(5985): p. 433-8.
130. Piechaczyk, M. and J.M. Blanchard, *c-fos proto-oncogene regulation and function*. Crit Rev Oncol Hematol, 1994. **17**(2): p. 93-131.

131. Hai, T. and T. Curran, *Cross-family dimerization of transcription factors Fos/Jun and ATF/CREB alters DNA binding specificity*. Proc Natl Acad Sci U S A, 1991. **88**(9): p. 3720-4.
132. Murphy, L.O., et al., *Molecular interpretation of ERK signal duration by immediate early gene products*. Nat Cell Biol, 2002. **4**(8): p. 556-64.
133. Shaulian, E. and M. Karin, *AP-1 in cell proliferation and survival*. Oncogene, 2001. **20**(19): p. 2390-400.
134. Dony, C. and P. Gruss, *Proto-oncogene c-fos expression in growth regions of fetal bone and mesodermal web tissue*. Nature, 1987. **328**(6132): p. 711-4.
135. Smeyne, R.J., T. Curran, and J.I. Morgan, *Temporal and spatial expression of a fos-lacZ transgene in the developing nervous system*. Brain Res Mol Brain Res, 1992. **16**(1-2): p. 158-62.
136. Grigoriadis, A.E., et al., *Osteoblasts are target cells for transformation in c-fos transgenic mice*. J Cell Biol, 1993. **122**(3): p. 685-701.
137. Lu, C., et al., *cFos is critical for MCF-7 breast cancer cell growth*. Oncogene, 2005. **24**(43): p. 6516-24.
138. Wyke, A.W., A. Lang, and M.C. Frame, *Uncoupling of the pathways which link MAP kinase to c-fos transcription and AP-1 in response to growth stimuli*. Cell Signal, 1996. **8**(2): p. 131-9.
139. Xing, J., et al., *Nerve growth factor activates extracellular signal-regulated kinase and p38 mitogen-activated protein kinase pathways to stimulate CREB serine 133 phosphorylation*. Mol Cell Biol, 1998. **18**(4): p. 1946-55.
140. Zhang, L., et al., *Role for the pleckstrin homology domain-containing protein CKIP-1 in AP-1 regulation and apoptosis*. EMBO J, 2005. **24**(4): p. 766-78.

141. Zerial, M., et al., *The product of a novel growth factor activated gene, fos B, interacts with JUN proteins enhancing their DNA binding activity.* EMBO J, 1989. **8**(3): p. 805-13.
142. Matsui, M., et al., *Isolation of human fos-related genes and their expression during monocyte-macrophage differentiation.* Oncogene, 1990. **5**(3): p. 249-55.
143. Gruda, M.C., et al., *Expression of FosB during mouse development: normal development of FosB knockout mice.* Oncogene, 1996. **12**(10): p. 2177-85.
144. Brown, J.R., et al., *A defect in nurturing in mice lacking the immediate early gene fosB.* Cell, 1996. **86**(2): p. 297-309.
145. Milde-Langosch, K., et al., *FosB is Highly Expressed in Normal Mammary Epithelia, but Down-Regulated in Poorly Differentiated Breast Carcinomas.* Breast Cancer Research and Treatment, 2003. **77**(3): p. 265-275.
146. Shirsat, N.V. and S.A. Shaikh, *Overexpression of the immediate early gene fra-1 inhibits proliferation, induces apoptosis, and reduces tumourigenicity of c6 glioma cells.* Exp Cell Res, 2003. **291**(1): p. 91-100.
147. Kustikova, O., et al., *Fra-1 induces morphological transformation and increases in vitro invasiveness and motility of epithelioid adenocarcinoma cells.* Mol Cell Biol, 1998. **18**(12): p. 7095-105.
148. Belguise, K., et al., *FRA-1 expression level regulates proliferation and invasiveness of breast cancer cells.* Oncogene, 2005. **24**(8): p. 1434-44.
149. Uht, R.M., et al., *A conserved lysine in the estrogen receptor DNA binding domain regulates ligand activation profiles at AP-1 sites, possibly by controlling interactions with a modulating repressor.* Nucl Recept, 2004. **2**(1): p. 2.
150. Nishina, H., et al., *Isolation and characterization of fra-2, an additional member of the fos gene family.* Proc Natl Acad Sci U S A, 1990. **87**(9): p. 3619-23.

151. Carrasco, D. and R. Bravo, *Tissue-specific expression of the fos-related transcription factor fra-2 during mouse development*. *Oncogene*, 1995. **10**(6): p. 1069-79.
152. Tulchinsky, E., *Fos family members: regulation, structure and role in oncogenic transformation*. *Histol Histopathol*, 2000. **15**(3): p. 921-8.
153. Wisdon, R. and I.M. Verma, *Transformation by Fos proteins requires a C-terminal transactivation domain*. *Mol Cell Biol*, 1993. **13**(12): p. 7429-38.
154. Milde-Langosch, K., *The Fos family of transcription factors and their role in tumourigenesis*. *Eur J Cancer*, 2005. **41**(16): p. 2449-61.
155. Shaulian, E. and M. Karin, *AP-1 as a regulator of cell life and death*. *Nat Cell Biol*, 2002. **4**(5): p. E131-6.
156. Wagner, E.F. and A.R. Nebreda, *Signal integration by JNK and p38 MAPK pathways in cancer development*. *Nat Rev Cancer*, 2009. **9**(8): p. 537-49.
157. Dhanasekaran, D.N. and E.P. Reddy, *JNK signaling in apoptosis*. *Oncogene*, 2008. **27**(48): p. 6245-51.
158. Weston, C.R. and R.J. Davis, *The JNK signal transduction pathway*. *Curr Opin Cell Biol*, 2007. **19**(2): p. 142-9.
159. Derijard, B., et al., *JNK1: a protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain*. *Cell*, 1994. **76**(6): p. 1025-37.
160. Hibi, M., et al., *Identification of an oncoprotein- and UV-responsive protein kinase that binds and potentiates the c-Jun activation domain*. *Genes Dev*, 1993. **7**(11): p. 2135-48.
161. Folkman, J., *Angiogenesis and c-Jun*. *J Natl Cancer Inst*, 2004. **96**(9): p. 644.
162. Laderoute, K.R., *The interaction between HIF-1 and AP-1 transcription factors in response to low oxygen*. *Semin Cell Dev Biol*, 2005. **16**(4-5): p. 502-13.
163. Periyakaruppan, A., et al., *Uranium induces oxidative stress in lung epithelial cells*. *Arch Toxicol*, 2007. **81**(6): p. 389-95.

164. Paolucci, L. and E. Rozengurt, *Protein kinase D in small cell lung cancer cells: rapid activation through protein kinase C*. *Cancer Res*, 1999. **59**(3): p. 572-7.
165. Nishizuka, Y., *Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C*. *Science*, 1992. **258**(5082): p. 607-14.
166. Parekh, D.B., W. Ziegler, and P.J. Parker, *Multiple pathways control protein kinase C phosphorylation*. *EMBO J*, 2000. **19**(4): p. 496-503.
167. Blobbe, G.C., et al., *Selective regulation of expression of protein kinase C (PKC) isoenzymes in multidrug-resistant MCF-7 cells. Functional significance of enhanced expression of PKC alpha*. *J Biol Chem*, 1993. **268**(1): p. 658-64.
168. Goode, N., et al., *Differential regulation of glycogen synthase kinase-3 beta by protein kinase C isotypes*. *J Biol Chem*, 1992. **267**(24): p. 16878-82.
169. Wetsel, W.C., et al., *Tissue and cellular distribution of the extended family of protein kinase C isoenzymes*. *J Cell Biol*, 1992. **117**(1): p. 121-33.
170. Koivunen, J., V. Aaltonen, and J. Peltonen, *Protein kinase C (PKC) family in cancer progression*. *Cancer Lett*, 2006. **235**(1): p. 1-10.
171. Skalhegg, B.S. and K. Tasken, *Specificity in the cAMP/PKA signaling pathway. Differential expression, regulation, and subcellular localization of subunits of PKA*. *Front Biosci*, 2000. **5**: p. D678-93.
172. Krebs, E.G. and J.A. Beavo, *Phosphorylation-dephosphorylation of enzymes*. *Annu Rev Biochem*, 1979. **48**: p. 923-59.
173. Roesler, W.J., G.R. Vandenbark, and R.W. Hanson, *Cyclic AMP and the induction of eukaryotic gene transcription*. *J Biol Chem*, 1988. **263**(19): p. 9063-6.
174. Tash, J.S., S.S. Kakar, and A.R. Means, *Flagellar motility requires the cAMP-dependent phosphorylation of a heat-stable NP-40-soluble 56 kd protein, axokinin*. *Cell*, 1984. **38**(2): p. 551-9.

175. Li, M., et al., *Convergent regulation of sodium channels by protein kinase C and cAMP-dependent protein kinase*. Science, 1993. **261**(5127): p. 1439-42.
176. Skroblin, P., et al., *Mechanisms of protein kinase A anchoring*. Int Rev Cell Mol Biol, 2010. **283**: p. 235-330.
177. Richards, J.S., *Hormonal control of gene expression in the ovary*. Endocr Rev, 1994. **15**(6): p. 725-51.
178. Gonzalez-Robayna, I.J., et al., *Follicle-Stimulating hormone (FSH) stimulates phosphorylation and activation of protein kinase B (PKB/Akt) and serum and glucocorticoid-induced kinase (Sgk): evidence for A kinase-independent signaling by FSH in granulosa cells*. Mol Endocrinol, 2000. **14**(8): p. 1283-300.
179. Bernard, K., et al., *Engagement of natural cytotoxicity programs regulates AP-1 expression in the NKL human NK cell line*. J Immunol, 1999. **162**(7): p. 4062-8.
180. Mukherjee, A., O.K. Park-Sarge, and K.E. Mayo, *Gonadotropins induce rapid phosphorylation of the 3',5'-cyclic adenosine monophosphate response element binding protein in ovarian granulosa cells*. Endocrinology, 1996. **137**(8): p. 3234-45.
181. Herdegen, T. and J.D. Leah, *Inducible and constitutive transcription factors in the mammalian nervous system: control of gene expression by Jun, Fos and Krox, and CREB/ATF proteins*. Brain Res Brain Res Rev, 1998. **28**(3): p. 370-490.
182. Ardekani, A.M., J.C. Romanelli, and K.E. Mayo, *Structure of the rat inhibin and activin betaA-subunit gene and regulation in an ovarian granulosa cell line*. Endocrinology, 1998. **139**(7): p. 3271-9.
183. Morgan, J.I. and T. Curran, *Stimulus-transcription coupling in the nervous system: involvement of the inducible proto-oncogenes fos and jun*. Annu Rev Neurosci, 1991. **14**: p. 421-51.
184. Freshney, *Culture of Animal Cells: A Manual of Basic Technique and Specialized Applications*. 2010, New York: Wiley - Blackwell.

185. Strober, W., *Trypan Blue Exclusion Test of Cell Viability*, in *Current Protocols in Immunology*. 2001, John Wiley & Sons, Inc.
186. Bryant, S. and D. Manning, *Formaldehyde Gel Electrophoresis of Total RNA*, in *RNA Isolation and Characterization Protocols*, R. Rapley and D. Manning, Editors. 1998, Humana Press. p. 69-72.
187. Surzycki, S., *Basic Techniques in Molecular Biology*. Springer Lab Manuals. 2000: Springer Berlin Heidelberg.
188. Yang, S.H., et al., *Mitochondrial localization of estrogen receptor beta*. *Proc Natl Acad Sci U S A*, 2004. **101**(12): p. 4130-5.
189. Osborne, C.K., H. Zhao, and S.A. Fuqua, *Selective estrogen receptor modulators: structure, function, and clinical use*. *J Clin Oncol*, 2000. **18**(17): p. 3172-86.
190. Liu, Y., et al., *Inhibition of AP-1 transcription factor causes blockade of multiple signal transduction pathways and inhibits breast cancer growth*. *Oncogene*, 2002. **21**(50): p. 7680-9.
191. Eferl, R. and E.F. Wagner, *AP-1: a double-edged sword in tumorigenesis*. *Nat Rev Cancer*, 2003. **3**(11): p. 859-68.
192. Shaulian, E., *AP-1--The Jun proteins: Oncogenes or tumor suppressors in disguise?* *Cell Signal*, 2010. **22**(6): p. 894-9.
193. Karin, M., *The regulation of AP-1 activity by mitogen-activated protein kinases*. *J Biol Chem*, 1995. **270**(28): p. 16483-6.
194. Pei, L., et al., *Regulation of the alpha inhibin gene by cyclic adenosine 3',5'-monophosphate after transfection into rat granulosa cells*. *Mol Endocrinol*, 1991. **5**(4): p. 521-34.
195. Milde-Langosch, K., et al., *FosB is highly expressed in normal mammary epithelia, but down-regulated in poorly differentiated breast carcinomas*. *Breast Cancer Research and Treatment*, 2003. **77**(3): p. 265-275.

196. Liu, Y.M., et al., *AP-1 blockade in breast cancer cells causes cell cycle arrest by suppressing G1 cyclin expression and reducing cyclin-dependent kinase activity*. *Oncogene*, 2004. **23**(50): p. 8238-8246.
197. Sharma, S.C., et al., *Expression and function of estrogen receptor subtypes in granulosa cells: regulation by estradiol and forskolin*. *Endocrinology*, 1999. **140**(9): p. 4320-34.
198. Bundred, N.J., *Prognostic and predictive factors in breast cancer*. *Cancer Treat Rev*, 2001. **27**(3): p. 137-42.
199. Huber, C., et al., *Antiestrogen therapy for breast cancer modifies the risk of subsequent cutaneous melanoma*. *Cancer Prev Res (Phila)*, 2012. **5**(1): p. 82-8.
200. Egawa, C., et al., *Quantitative analysis of estrogen receptor-alpha and -beta messenger RNA expression in normal and malignant thyroid tissues by real-time polymerase chain reaction*. *Oncology*, 2001. **61**(4): p. 293-8.
201. Roger, P., et al., *Decreased expression of estrogen receptor beta protein in proliferative preinvasive mammary tumors*. *Cancer Res*, 2001. **61**(6): p. 2537-41.
202. *Tamoxifen for early breast cancer: an overview of the randomised trials*. *Early Breast Cancer Trialists' Collaborative Group*. *Lancet*, 1998. **351**(9114): p. 1451-67.
203. Miner, J.N., M.I. Diamond, and K.R. Yamamoto, *Joints in the regulatory lattice: composite regulation by steroid receptor-AP1 complexes*. *Cell Growth Differ*, 1991. **2**(10): p. 525-30.
204. Pfahl, M., *Nuclear receptor/AP-1 interaction*. *Endocr Rev*, 1993. **14**(5): p. 651-8.
205. Ponta, H., A.C. Cato, and P. Herrlich, *Interference of pathway specific transcription factors*. *Biochim Biophys Acta*, 1992. **1129**(3): p. 255-61.
206. Philips, A., D. Chalbos, and H. Rochefort, *Estradiol increases and anti-estrogens antagonize the growth factor-induced activator protein-1 activity in MCF7 breast*

- cancer cells without affecting c-fos and c-jun synthesis.* J Biol Chem, 1993. **268**(19): p. 14103-8.
207. Yang-Yen, H.F., et al., *Antagonism between retinoic acid receptors and AP-1: implications for tumor promotion and inflammation.* New Biol, 1991. **3**(12): p. 1206-19.
208. Teyssier, C., et al., *Characterization of the physical interaction between estrogen receptor alpha and JUN proteins.* J Biol Chem, 2001. **276**(39): p. 36361-9.
209. Lee, S.K., et al., *Steroid receptor coactivator-1 coactivates activating protein-1-mediated transactivations through interaction with the c-Jun and c-Fos subunits.* J Biol Chem, 1998. **273**(27): p. 16651-4.
210. Jakacka, M., et al., *Estrogen receptor binding to DNA is not required for its activity through the nonclassical AP1 pathway.* J Biol Chem, 2001. **276**(17): p. 13615-21.
211. Awasthi, S., A. Daverey, and A. Dwivedi, *Modulation of AP-1 mediated estrogenic response by ormeloxifene in rat uterus.* J Steroid Biochem Mol Biol, 2007. **104**(3-5): p. 208-14.
212. Heximer, S.P., et al., *Sequence analysis and expression in cultured lymphocytes of the human FOSB gene (G0S3).* DNA Cell Biol, 1996. **15**(12): p. 1025-38.
213. Ransone, L.J., et al., *fos and jun interaction: the role of the leucine zipper.* Int J Cancer Suppl, 1989. **4**: p. 10-21.
214. Milde-Langosch, K., et al., *Role of Fra-2 in breast cancer: influence on tumor cell invasion and motility.* Breast Cancer Res Treat, 2008. **107**(3): p. 337-47.
215. Verdier-Sevrain, S., et al., *Estradiol induces proliferation of keratinocytes via a receptor mediated mechanism.* FASEB J, 2004. **18**(11): p. 1252-4.
216. Stender, J.D., et al., *Estrogen-regulated gene networks in human breast cancer cells: involvement of E2F1 in the regulation of cell proliferation.* Mol Endocrinol, 2007. **21**(9): p. 2112-23.

217. Wang, A., et al., *Regulation of BRCA1 expression by the Rb-E2F pathway*. J Biol Chem, 2000. **275**(6): p. 4532-6.
218. Perillo, B., et al., *17beta-estradiol inhibits apoptosis in MCF-7 cells, inducing bcl-2 expression via two estrogen-responsive elements present in the coding sequence*. Mol Cell Biol, 2000. **20**(8): p. 2890-901.
219. Bjornstrom, L. and M. Sjoberg, *Mechanisms of Estrogen Receptor Signalling: Convergence of Genomic and Nongenomic Actions on Target Genes*. Mol Endocrinology, 2005. **19**: p. 833-842.
220. Al-Hajj, M., et al., *Prospective identification of tumorigenic breast cancer cells*. Proc Natl Acad Sci U S A, 2003. **100**(7): p. 3983-8.
221. Welm, B., et al., *Isolation and characterization of functional mammary gland stem cells*. Cell Prolif, 2003. **36 Suppl 1**: p. 17-32.
222. Wu, J., *Apoptosis and angiogenesis: two promising tumor markers in breast cancer (review)*. Anticancer Res, 1996. **16**(4B): p. 2233-9.
223. Furth, P., *Apoptosis and the development of breast cancer* in *Breast Cancer: Molecular Genetics, Pathogenesis, and Therapeutics*, A. Bowcock, Editor. 1999, Humana Press: New Jersey. p. pp171-180.
224. Baselga, J. and J. Mendelsohn, *The epidermal growth factor receptor as a target for therapy in breast carcinoma*. Breast Cancer Res Treat, 1994. **29**(1): p. 127-38.
225. Sarup, J.C., et al., *Characterization of an anti-p185HER2 monoclonal antibody that stimulates receptor function and inhibits tumor cell growth*. Growth Regul, 1991. **1**(2): p. 72-82.
226. Drebin, J.A., V.C. Link, and M.I. Greene, *Monoclonal antibodies reactive with distinct domains of the neu oncogene-encoded p185 molecule exert synergistic anti-tumor effects in vivo*. Oncogene, 1988. **2**(3): p. 273-7.

227. Debatin, K., *Activation of apoptosis pathways by anticancer treatment*. Toxicol Lett, 2000. **112-113**: p. 41-8.
228. Shao, Z.M., et al., *Neo-adjuvant chemotherapy for operable breast cancer induces apoptosis*. Breast Cancer Res Treat, 1999. **53**(3): p. 263-9.
229. Simstein, R., et al., *Apoptosis, chemoresistance, and breast cancer: insights from the MCF-7 cell model system*. Exp Biol Med (Maywood), 2003. **228**(9): p. 995-1003.
230. Campbell, R.A., et al., *Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance*. J Biol Chem, 2001. **276**(13): p. 9817-24.
231. Gottesman, M.M. and R.D. Fleischmann, *The role of cAMP in regulating tumour cell growth*. Cancer Surv, 1986. **5**(2): p. 291-308.
232. Stork, P.J. and J.M. Schmitt, *Crosstalk between cAMP and MAP kinase signaling in the regulation of cell proliferation*. Trends Cell Biol, 2002. **12**(6): p. 258-66.
233. Sevetson, B.R., X. Kong, and J.C. Lawrence, Jr., *Increasing cAMP attenuates activation of mitogen-activated protein kinase*. Proc Natl Acad Sci U S A, 1993. **90**(21): p. 10305-9.
234. D'Angelo, G., H. Lee, and R.I. Weiner, *cAMP-dependent protein kinase inhibits the mitogenic action of vascular endothelial growth factor and fibroblast growth factor in capillary endothelial cells by blocking Raf activation*. J Cell Biochem, 1997. **67**(3): p. 353-66.
235. Chen, J. and R. Iyengar, *Suppression of Ras-induced transformation of NIH 3T3 cells by activated G alpha s*. Science, 1994. **263**(5151): p. 1278-81.
236. Thoresen, G.H., E.J. Johasen, and T. Christoffersen, *Effects of cAMP on ERK mitogen-activated protein kinase activity in hepatocytes do not parallel the bidirectional regulation of DNA synthesis*. Cell Biol Int, 1999. **23**(1): p. 13-20.

237. Richards, J.S., *New signaling pathways for hormones and cyclic adenosine 3',5'-monophosphate action in endocrine cells*. Mol Endocrinol, 2001. **15**(2): p. 209-18.
238. Dempsey, E.C., et al., *Protein kinase C isozymes and the regulation of diverse cell responses*. Am J Physiol Lung Cell Mol Physiol, 2000. **279**(3): p. L429-38.
239. Sabri, A. and S.F. Steinberg, *Protein kinase C isoform-selective signals that lead to cardiac hypertrophy and the progression of heart failure*. Mol Cell Biochem, 2003. **251**(1-2): p. 97-101.
240. Steinberg, S.F., *Structural Basis of Protein Kinase C Isoform Function*. Physiol Rev 2008. **88**: p. 1341–1378.
241. Babu, R.L., et al., *Effect of estrogen and tamoxifen on the expression pattern of AP-1 factors in MCF-7 cells: role of c-Jun, c-Fos, and Fra-1 in cell cycle regulation*. Mol Cell Biochem. DOI 10.1007/s11010-013-1667-x, 2013.
242. Bradford, M.M., *A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding*. Anal Biochem, 1976. **72**: p. 248-54.
243. Compton, S.J. and C.G. Jones, *Mechanism of dye response and interference in the Bradford protein assay*. Anal Biochem, 1985. **151**(2): p. 369-74.
244. Garfin, D.E., *One-dimensional gel electrophoresis*. Methods Enzymol, 2009. **463**: p. 497-513.
245. Towbin, H., T. Staehelin, and J. Gordon, *Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications*. 1979. Biotechnology, 1992. **24**: p. 145-9.
246. *Tamoxifen for early breast cancer: an overview of the randomised trials*. . Lancet, Early Breast Cancer Trialists' Collaborative Group 1998. **351**(9114): p. 1451-67.

247. Duan, R., W. Porter, and S. Safe, *Estrogen-induced c-fos protooncogene expression in MCF-7 human breast cancer cells: role of estrogen receptor Sp1 complex formation*. *Endocrinology*, 1998. **139**(4): p. 1981-90.
248. Philips, A., et al., *FRA-1 expression level modulates regulation of activator protein-1 activity by estradiol in breast cancer cells*. *Mol Endocrinol*, 1998. **12**(7): p. 973-85.
249. Ramos-Nino, M.E., C.R. Timblin, and B.T. Mossman, *Mesothelial cell transformation requires increased AP-1 binding activity and ERK-dependent Fra-1 expression*. *Cancer Res*, 2002. **62**(21): p. 6065-9.
250. Ramos-Nino, M.E., et al., *Microarray analysis and RNA silencing link fra-1 to cd44 and c-met expression in mesothelioma*. *Cancer Res*, 2003. **63**(13): p. 3539-45.
251. Zhang, W., et al., *Differential expression of the AP-1 transcription factor family members in human colorectal epithelial and neuroendocrine neoplasms*. *Am J Clin Pathol*, 2005. **124**(1): p. 11-9.
252. Milde-Langosch, K., et al., *FosB is highly expressed in normal mammary epithelia, but down-regulated in poorly differentiated breast carcinomas*. *Breast Cancer Res Treat*, 2003. **77**(3): p. 265-75.
253. Dahlman-Wright, K., et al., *Interplay between AP-1 and estrogen receptor alpha in regulating gene expression and proliferation networks in breast cancer cells*. *Carcinogenesis*, 2012. **33**(9): p. 1684-91.
254. Liu, Y., et al., *AP-1 blockade in breast cancer cells causes cell cycle arrest by suppressing G1 cyclin expression and reducing cyclin-dependent kinase activity*. *Oncogene*, 2004. **23**(50): p. 8238-46.
255. Zhao, C., et al., *Genome-wide mapping of estrogen receptor-beta-binding regions reveals extensive cross-talk with transcription factor activator protein-1*. *Cancer Res*, 2010. **70**(12): p. 5174-83.

256. Heinrich, R. and Z. Kraiem, *The protein kinase A pathway inhibits c-jun and c-fos protooncogene expression induced by the protein kinase C and tyrosine kinase pathways in cultured human thyroid follicles*. J Clin Endocrinol Metab, 1997. **82**(6): p. 1839-44.
257. Lee, J.K., et al., *Differential effects of forskolin and phobol 12-myristate-13-acetate on the c-fos and c-jun mRNA expression in rat C6 glioma cells*. Mol Cells, 2001. **12**(1): p. 11-6.
258. Du, J., et al., *Arsenic induces functional re-expression of estrogen receptor alpha by demethylation of DNA in estrogen receptor-negative human breast cancer*. PLoS One, 2012. **7**(4): p. e35957.
259. Chung, S., et al., *Overexpressing PKIB in prostate cancer promotes its aggressiveness by linking between PKA and Akt pathways*. Oncogene, 2009. **28**(32): p. 2849-59.
260. Dalton, G.D. and W.L. Dewey, *Protein kinase inhibitor peptide (PKI): a family of endogenous neuropeptides that modulate neuronal cAMP-dependent protein kinase function*. Neuropeptides, 2006. **40**(1): p. 23-34.
261. Vuaroqueaux, V., et al., *Low E2F1 transcript levels are a strong determinant of favorable breast cancer outcome*. Breast Cancer Res, 2007. **9**(3): p. R33.
262. Lapenna, S. and A. Giordano, *Cell cycle kinases as therapeutic targets for cancer*. Nat Rev Drug Discov, 2009. **8**(7): p. 547-66.
263. Hartwell, L.H. and T.A. Weinert, *Checkpoints: controls that ensure the order of cell cycle events*. Science, 1989. **246**(4930): p. 629-34.
264. Weinberg, R.A., *The retinoblastoma protein and cell cycle control*. Cell, 1995. **81**(3): p. 323-30.
265. Sherr, C.J., *Cancer cell cycles*. Science, 1996. **274**(5293): p. 1672-7.
266. Roy, P.G. and A.M. Thompson, *Cyclin D1 and breast cancer*. Breast, 2006. **15**(6): p. 718-27.

267. Massague, J., *G1 cell-cycle control and cancer*. Nature, 2004. **432**(7015): p. 298-306.
268. Lukas, J., et al., *Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16*. Nature, 1995. **375**(6531): p. 503-6.
269. Li, J., M.J. Poi, and M.D. Tsai, *Regulatory mechanisms of tumor suppressor P16(INK4A) and their relevance to cancer*. Biochemistry, 2011. **50**(25): p. 5566-82.
270. Witkiewicz, A.K., et al., *The meaning of p16(ink4a) expression in tumors: functional significance, clinical associations and future developments*. Cell Cycle, 2011. **10**(15): p. 2497-503.
271. Paternot, S., et al., *Rb inactivation in cell cycle and cancer: the puzzle of highly regulated activating phosphorylation of CDK4 versus constitutively active CDK-activating kinase*. Cell Cycle, 2010. **9**(4): p. 689-99.
272. Rocco, J.W. and D. Sidransky, *p16(MTS-1/CDKN2/INK4a) in cancer progression*. Exp Cell Res, 2001. **264**(1): p. 42-55.
273. Santamaria, D., et al., *Cdk1 is sufficient to drive the mammalian cell cycle*. Nature, 2007. **448**(7155): p. 811-5.
274. Thoms, H.C., M.G. Dunlop, and L.A. Stark, *CDK4 inhibitors and apoptosis: a novel mechanism requiring nucleolar targeting of RelA*. Cell Cycle, 2007. **6**(11): p. 1293-7.
275. Poomsawat, S., et al., *Alteration in the expression of cdk4 and cdk6 proteins in oral cancer and premalignant lesions*. J Oral Pathol Med, 2010. **39**(10): p. 793-9.
276. Lindberg, D., et al., *Cyclin-dependent kinase 4 (CDK4) expression in pancreatic endocrine tumors*. Neuroendocrinology, 2007. **86**(2): p. 112-8.
277. Fang, W., et al., *Transcriptional patterns, biomarkers and pathways characterizing nasopharyngeal carcinoma of Southern China*. J Transl Med, 2008. **6**: p. 32.
278. Wikman, H., et al., *CDK4 is a probable target gene in a novel amplicon at 12q13.3-q14.1 in lung cancer*. Genes Chromosomes Cancer, 2005. **42**(2): p. 193-9.

279. Dobashi, Y., et al., *Overexpression of cdk4/cyclin D1, a possible mediator of apoptosis and an indicator of prognosis in human primary lung carcinoma*. Int J Cancer, 2004. **110**(4): p. 532-41.
280. Zamecnik, P.C. and M.L. Stephenson, *Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide*. Proc Natl Acad Sci U S A, 1978. **75**(1): p. 280-4.
281. Crooke, S.T., *Progress in antisense technology*. Annu Rev Med, 2004. **55**: p. 61-95.
282. Chan, J.H., S. Lim, and W.S. Wong, *Antisense oligonucleotides: from design to therapeutic application*. Clin Exp Pharmacol Physiol, 2006. **33**(5-6): p. 533-40.
283. Eckstein, F., *Phosphorothioate oligodeoxynucleotides: What is their origin and what is unique about them?* Antisense & Nucleic Acid Drug Development, 2000. **10**(2): p. 117-121.
284. Crooke, S.T., *Progress in antisense technology: The end of the beginning*. Antisense Technology, Pt A, 2000. **313**: p. 3-45.
285. Kurreck, J., *Antisense technologies - Improvement through novel chemical modifications*. European Journal of Biochemistry, 2003. **270**(8): p. 1628-1644.
286. Gleave, M.E. and B.P. Monia, *Antisense therapy for cancer*. Nature Reviews Cancer, 2005. **5**(6): p. 468-479.
287. Groskreutz, D. and E.T. Schenborn, *Reporter systems*. Methods Mol Biol, 1997. **63**: p. 11-30.
288. Zhang, L., et al., *Antisense oligonucleotide targeting c-fos mRNA limits retinal pigment epithelial cell proliferation: a key step in the progression of proliferative vitreoretinopathy*. Exp Eye Res, 2006. **83**(6): p. 1405-11.
289. Zhou, Y.Q., et al., *Altered expression of the RON receptor tyrosine kinase in primary human colorectal adenocarcinomas: generation of different splicing RON variants and their oncogenic potential*. Oncogene, 2003. **22**(2): p. 186-97.

290. Phuchareon, J. and T. Tokuhisa, *Deregulated c-Fos/AP-1 modulates expression of the cyclin and the cdk gene in splenic B cells stimulated with lipopolysaccharide*. *Cancer Lett*, 1995. **92**(2): p. 203-8.
291. Cargnello, M. and P.P. Roux, *Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases*. *Microbiol Mol Biol Rev*, 2011. **75**(1): p. 50-83.
292. Vanden Bush, T.J. and G.A. Bishop, *CDK-mediated regulation of cell functions via c-Jun phosphorylation and AP-1 activation*. *PLoS One*, 2011. **6**(4): p. e19468.
293. Arteaga, C.L. and J.T. Holt, *Tissue-targeted antisense c-fos retroviral vector inhibits established breast cancer xenografts in nude mice*. *Cancer Res*, 1996. **56**(5): p. 1098-1103.

Publications and Abstracts

List of publications

List of papers generated from this thesis

1. **Babu R L**, Naveen Kumar M, Rajeshwari H Patil, Devaraju K S, Govindarajan T Ramesh, S. Chidananda Sharma. **Effect of estrogen and tamoxifen on the expression pattern of AP-1 factors in MCF-7 cells: role of c-Jun, c-Fos, and Fra-1 in cell cycle regulation.** *Mol Cell Biochem*, 380(1-2), 143-151, 2013
2. **Babu R L**, Vijayalakshmi E, Naveen Kumar M, Rajeshwari H Patil, S. Chidananda Sharma. **Blocking of CDK4 Gene Expression by Antisense Oligos Induce Apoptosis and Decreases the Proliferation of A549 Cells.** *Int. Jour. of scientific research*, 2 (8), 51-53, 2013.
3. **Babu R L**, Naveen Kumar M, Rajeshwari H Patil, Kiran Kumar K M, Govindarajan T Ramesh and S. Chidananda Sharma. **Forskolin inhibits PMA induced expression of mRNAs of AP-1 factors (c-Jun/c-Fos and Fra1) in MCF-7 cells. Antisense oligos of c-Jun and c-Fos inhibits the cell proliferation.**
Under review in *Molecular and Cellular Biochemistry*.

Papers presented at national and international conferences

Oral presentation

1. **Babu R L**, Vijayalakshmi E and S. Chidananda Sharma. *Effect of Estradiol-17 β and Tamoxifen on proliferation of MCF-7 cells* at International conference on *Recent trends in therapeutic advancement in free radical science and cancer* jointly organized by Bharathi women's college Chennai and Angiogenesis laboratory, University of Connecticut, USA. Jan 9-11, 2010 at Chennai.
2. **Babu R L** and S. Chidananda Sharma. *Effect of estrogen and tamoxifen on the expression pattern of AP-1 factors in MCF-7 cells* at 11th *all India conference on cytology and genetics*, organized by Bangalore University. Jan 23-25, 2012 at Bangalore
3. **Babu R L**, Vijayalakshmi E, Naveen Kumar M, Rajeshwari H Patil and S. Chidananda Sharma. *Effect of Estrogen and Tamoxifen on the expression pattern of AP-1 factors in MCF-7 cells* at *International Conference of the Asian Clinical Oncology Society*. June 13-15, 2012 COEX, Seoul, Korea

Poster presentation

1. **Babu R L**, Vijayalakshmi E, Naveen Kumar M, Rajeshwari H Patil and S. Chidananda Sharma. *Upregulation of proto-oncogenes (c-Jun, c-Fos and Fra-1) induces the breast cancer cell (MCF-7) proliferation* at *national level conference and workshop on computational biology, pharmaceuticals & life sciences*, organized by Maharani Laxmi Ammanni College for Women's, Malleshwaram, Bangalore. Nov 23-24, 2012.

2. **Babu RL**, Vijayalakshmi E, Naveen Kumar M, Rajeshwari H Patil and S. Chidananda Sharma. *Cloning of CDK-4 gene and effect of antisense Oligonucleotides proliferation of A-549 cells* at *National conference on recent trends in proteomics and genomics*. Dept. of microbiology and Biotechnology, Bangalore University and Indian academy college Bangalore. May 26-27, 2011.
3. **Babu R L**, Vijayalakshmi. E, Rajeshwari H Patil, Naveen Kumar. M and S. Chidananda Sharma. *Phorbol 12-Myristate 13- Acetate induces the proliferation and expression of c-Jun, c-Fos and Fra-1 in MCF-7 cells* at *World Congress on Biotechnology* at Leonia convention, Hyderabad. May 04-06, 2012.

Awards received

1. **Prof. D. V. Dayanadasagar Young Scientist Award** from *National Society of Cytologist and Geneticists* for outstanding paper. *Effect of estrogen and tamoxifen on the expression pattern of AP-1 factors in MCF-7 cells* at 11th *all India conference on cytology and genetics*, organized by Bangalore University, Bangalore. Jan 23-25, 2012.
2. Awarded **Special Prize and recognized as outstanding paper**. *Upregulation of proto-oncogenes (c-Jun, c-Fos and Fra-1) induces the breast cancer cell (MCF-7) proliferation* at *national level conference and workshop on computational biology, pharmaceuticals & life sciences*, organized by Maharani Laxmi Ammanni College for Women's, Malleshwaram, Bangalore. Nov 23-24, 2012.